Telomir Pharmaceuticals Breakthrough in Silver-Based Medicine

Telomir Pharmaceuticals (NASDAQ: TELO) has achieved a major scientific breakthrough by stabilizing Silver(II) (Ag²⁺) using its proprietary compound, Telomir-1. This advancement overcomes a key challenge in silver-based medicine, unlocking new possibilities for antimicrobial treatments, wound care, and infection-resistant medical coatings.

Silver(II) offers superior antibacterial action, faster wound healing, and immune-modulating properties compared to traditional Silver(I) (Ag⁺). However, its instability has limited its medical use—until now. Telomir-1 enables a biologically safe and controlled release of Silver(II), opening new doors in healthcare.

With the silver wound dressings market projected to reach $1.36 billion by 2030 and the antimicrobial coatings market set to hit $33.7 billion by 2031, Telomir’s innovation positions it as a leader in the field. The company is advancing clinical research and regulatory approvals, potentially transforming infection control and wound healing treatments.

You might like this article: flyExclusive to Acquire Jet.AI’s Aviation Business in Strategic Expansion